RJA
CRMD icon

Raymond James & Associates’s CorMedix CRMD Stock Holding History

Raymond James & Associates’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$387K Sell
47,837
-1,995
-4% -$10.8K ﹤0.01% 3257
2024
Q2 		$216K Buy
49,832
+4,005
+9% +$20.3K ﹤0.01% 3562
2024
Q1 		$194K Buy
45,827
+3,000
+7% +$10.4K ﹤0.01% 3624
2023
Q4 		$161K Buy
42,827
+5,800
+16% +$20K ﹤0.01% 3563
2023
Q3 		$137K Buy
37,027
+200
+0.5% +$795 ﹤0.01% 3544
2023
Q2 		$146K Buy
36,827
+2,000
+6% +$9.89K ﹤0.01% 3553
2023
Q1 		$144K Buy
34,827
+1,200
+4% +$4.91K ﹤0.01% 3570
2022
Q4 		$142K Hold
33,627
– – ﹤0.01% 3553
2022
Q3 		$95K Hold
33,627
– – ﹤0.01% 3616
2022
Q2 		$135K Hold
33,627
– – ﹤0.01% 3616
2022
Q1 		$184K Sell
33,627
-2,599
-7% -$11.9K ﹤0.01% 3692
2021
Q4 		$165K Buy
36,226
+3,815
+12% +$18.9K ﹤0.01% 3759
2021
Q3 		$151K Buy
32,411
+11,137
+52% +$64.9K ﹤0.01% 3736
2021
Q2 		$146K Sell
21,274
-2,825
-12% -$22.5K ﹤0.01% 3761
2021
Q1 		$241K Buy
24,099
+1,899
+9% +$20K ﹤0.01% 3496
2020
Q4 		$165K Hold
22,200
– – ﹤0.01% 3460
2020
Q3 		$134K Buy
22,200
+12,087
+120% +$60.7K ﹤0.01% 3325
2020
Q2 		$64K Sell
10,113
-340
-3% -$1.57K ﹤0.01% 3354
2020
Q1 		$38K Buy
+10,453
New +$59K ﹤0.01% 3351

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James & Associates's CRMD Position: Q3 2024 in Review

Raymond James & Associates reduced its CorMedix (CRMD) stake by 4% in Q3 2024, selling an estimated $10.8K and leaving 47,837 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #3257.

Raymond James & Associates first reported a position in CRMD in Q1 2020 and has held it in 19 quarters since. 102 funds tracked by Wall St. Rank hold CRMD as of Q3 2024.

  • Raymond James & Associates held 47,837 shares of CorMedix worth $387K as of Q3 2024.
  • Raymond James & Associates sold 1,995 CorMedix shares in Q3 2024, an estimated $10.8K.
  • CorMedix made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3257 holding.
  • Raymond James & Associates first reported a position in CorMedix in Q1 2020 and has held it in 19 quarters since.
  • 102 funds tracked by Wall St. Rank held CorMedix as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.